Pioglitazone to protect kidney function in ANCA vasculitis
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This Phase 3 trial tests whether pioglitazone can help protect kidney function in people with newly diagnosed or relapsing ANCA-associated vasculitis that is actively affecting the kidneys. It aims to improve “renal tolerance,” meaning your kidneys may be better able to tolerate the disease and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ANCA-associated vasculitis (GPA or MPA) that is active right now, based on kidney symptoms and a score (BVAS ≥ 3).
- You have kidney involvement showing abnormal urine tests (protein in urine and blood in urine) and your kidney filtration is not too low (eGFR ≥ 15).
- You had a kidney biopsy within the last 4 weeks confirming active disease in the kidneys.
- You are between 18 and 80 years old, and you can sign informed consent.
- You are in the French health insurance system (or an eligible beneficiary).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This study tests whether pioglitazone, a medicine commonly used for diabetes, can slow the worsening of a condition called calcific aortic valve disease, where calcium builds up on the heart's aortic valve. It may help patients with mild to moderate valve narrowing avoid the need for surgery.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.